Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARBIDOH: Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in MSA-P and PD
NCT06831500Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carbidopa and levodopa in Parkinson's disease (PD) and multiple system atrophy (MSA) (3 arms). Primary endpoint: Feasibility of future large-scale double-blind randomized controlled trial (RCT) at 5 weeks. Started Jul 2025; status: recruiting.
02
Drugs
carbidopalevodopa
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06831500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831500.